Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

PDE5 inhibitors and pulmonary hypertension

PDE5 inhibitors and pulmonary hypertension Phosphodiesterases (PDEs) are important components in cellular signaling in many vascular beds. Although the most recognized PDE inhibitor, sildenafil, a specific PDE5 inhibitor, is best known for its effect on the penile vascular bed resulting in erection, it also has therapeutic effects in other vascular beds, including the coronary and pulmonary vasculature. The first large, randomized, double-blind, placebo-controlled clinical trial using sildenafil in patients with pulmonary arterial hypertension was reported in 2005. As a result of this and other studies, sildenafil is now used to treat idiopathic pulmonary hypertension. Future studies are required to assess the potential use of other PDE5 antagonists and combination therapy on pulmonary hemodynamics, functional capacity, and long-term prognosis in the treatment of pulmonary arterial hypertension. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Current Sexual Health Reports Springer Journals

PDE5 inhibitors and pulmonary hypertension

Loading next page...
 
/lp/springer-journals/pde5-inhibitors-and-pulmonary-hypertension-0vEHYqiAJZ

References (65)

Publisher
Springer Journals
Copyright
Copyright © 2008 by Springer Science+Business Media, LLC
Subject
Medicine & Public Health; Urology; Endocrinology
ISSN
1548-3584
eISSN
1548-3592
DOI
10.1007/s11930-008-0031-8
Publisher site
See Article on Publisher Site

Abstract

Phosphodiesterases (PDEs) are important components in cellular signaling in many vascular beds. Although the most recognized PDE inhibitor, sildenafil, a specific PDE5 inhibitor, is best known for its effect on the penile vascular bed resulting in erection, it also has therapeutic effects in other vascular beds, including the coronary and pulmonary vasculature. The first large, randomized, double-blind, placebo-controlled clinical trial using sildenafil in patients with pulmonary arterial hypertension was reported in 2005. As a result of this and other studies, sildenafil is now used to treat idiopathic pulmonary hypertension. Future studies are required to assess the potential use of other PDE5 antagonists and combination therapy on pulmonary hemodynamics, functional capacity, and long-term prognosis in the treatment of pulmonary arterial hypertension.

Journal

Current Sexual Health ReportsSpringer Journals

Published: Nov 25, 2008

There are no references for this article.